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1. Introduction 
Cholangiocarcinoma is a type of liver cancer arising from the neoplastic transformation of 
the epithelial cells that line the intra- and extrahepatic bile ducts. Symptoms are usually 
evident only after blockage of the bile duct by the tumor. This is an extremely aggressive 
tumor, which has very poor prognosis and limited treatment options. Cholangiocarcinoma 
is relatively resistant to chemotherapy and radiation therapy leaving conventional treatment 
like surgery as the only option. Therefore, further understanding into the factors that are 
involved in tumor initiation, promotion and progression is required for designing alternate 
therapies to combat this devastating disease.  
The tumor microenvironment is one of the most important factors regulating tumor 
angiogenesis, tumor invasion and metastasis. The microenvironment is a well-recognized 
system that plays a key role in tumor progression. However, the mechanism through which 
tumor microenvironment regulates tumor progression and invasion is largely unknown. In 
this review, we discuss the current knowledge about the role of the tumor 
microenvironment in the pathogenesis of cholangiocarcinoma, the role of the tumor 
microenvironment in the classification of cholangiocarcinoma and efforts to develop 
treatments targeting the tumor microenvironment.  
2. Background 
Cholangiocarcinoma arises from the neoplastic transformation of cholangiocytes and can 
exist as either intrahepatic, perihilar or distal extrahepatic tumors (Alpini et al. 2001). 
Typically, cholangiocarcinomas are adenocarcinomas and have a poor prognosis and 
limited treatment options. This is due, at least in part, to the late presentation of symptoms 
and the relative resistance to current treatment options (Sirica 2005).  
The incidence of both intra- and extra-hepatic cholangiocarcinoma is typically more 
prevalent in Asian countries (Patel 2002). The mortality rates for intrahepatic 
cholangiocarcinoma have increased since the 1970s, whereas deaths from extrahepatic 
cholangiocarcinoma have declined in most countries (Patel 2002). There is a slight 
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preponderance for cholangiocarcinoma in males (Tominaga and Kuroishi 1994) and the 
incidence in both sexes increases with age (Patel 2002). 
2.1 Risk factors 
Cholangiocarcinoma occurs with varying frequency in different regions of the world. This 
can be explained in part by the distribution of risk factors in geographic regions and ethnic 
groups (Ben-Menachem 2007). The common link between these regional risk factors seems 
to involve chronic inflammation and biliary irritation (Gores 2003). 
The prevalence of cholangiocarcinoma in Asian countries shares a relationship with 
infections such as liver flukes, Hepatitis B and Hepatitis C (Ben-Menachem 2007). In 
contrast, approximately 90% of patients diagnosed with cholangiocarcinoma in Western 
countries do not have any recognized risk factors (Ben-Menachem 2007). However, the 
remaining 10% of cases are associated with certain risk factors. Apart from factors related to 
chronic inflammation, both intra- and extrahepatic cholangiocarcinomas are well-known 
complications of primary sclerosing cholangitis (de Groen et al. 1999). Other known risk 
factors include obesity, hepatolithiasis, bacterial infection and/or bile stasis-related chronic 
cholangitis (Chen 1999; de Groen et al. 1999; Catalano et al. 2009). 
3. Tumor microenvironment 
Neoplastic epithelial cells coexist with a biologically complex stroma composed of various 
types of stromal cells as well as the extracellular matrix, both of which create the complexity 
of the tumor microenvironment (Orimo and Weinberg 2006). Mouse models of 
tumorigenesis have revealed that stromal cells, in particular inflammatory cells, vascular 
endothelial cells and fibroblasts actively support tumor growth (Olumi et al. 1999; Tlsty 
2001; Cunha et al. 2003; Bhowmick et al. 2004). In addition, the microenvironment is now 
well recognized as playing a role in neoplastic transformation, malignant progression and 
metastasis and invasion of cancer cells (Tlsty 2001; Bhowmick et al. 2004). Furthermore, the 
interaction between the cancer cells and the tumor microenvironment is a major factor 
influencing cancer treatment resistance to radiotherapy and chemotherapy (de Visser and 
Jonkers 2009; Shinohara and Maity 2009). Research indicates that the interplay between the 
cancer cells and the stromal cells of the microenvironment is bi-directional and dynamic. For 
example, neoplastic cells often secrete factors that work in a paracrine manner to recruit and 
activate a number of types of stromal cells into the tumor microenvironment as required 
(Rasanen and Vaheri 2010; Rojas et al. 2010; Onimaru and Yonemitsu 2011). Conversely, 
stromal cells, once recruited and activated, release factors into the extracellular milieu that 
can either stimulate or inhibit growth of the tumor (Rasanen and Vaheri 2010; Rojas et al. 
2010; Onimaru and Yonemitsu 2011). The effects of the components of the tumor 
microenvironment on tumor growth are summarized in Figure 1. In particular, the 
proliferation and recruitment of vascular endothelial cells and subsequent formation of new 
blood vessels brings a nutrient supply thereby allowing growth and metastasis of the tumor. 
Cancer associated fibroblasts, on the other hand, can stimulate angiogenesis as well promote 
tumor growth and invasion. The presence of immune cells, in particular tumor-associated 
macrophages, in the microenvironment, confers resistance to toxic insults and also promotes 
growth. Lastly, proliferation of lymph endothelial cells and subsequent increase in 
lymphatic vessel density promotes tumor metastasis. 
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Fig. 1. Schematic representation of the effects of stromal support cells on tumor growth and 
metastasis. Abbreviations: B, B cell; BV, Blood vessel; EMT, Epithelial-mesenchymal 
transition; LV, lymph vessel; M, monocyte; T, T cell; TAM, Tumor associated macrophage. 
3.1 Angiogenesis 
The physiological process of the formation of new blood vessels from pre-existing blood 
vessels is termed angiogenesis. Tumors require the formation of new blood vessels to 
supply oxygen and other essential nutrients, without which their growth would be severely 
restricted (McDougall et al. 2006). Generally, the process of angiogenesis involves a 
sequence of co-ordinated events that is initiated with the expression and release of various 
angiogenic factors from the tumor cells, such as vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF) and fibroblast growth factor (FGF). Once these angiogenic 
factors bind to their corresponding receptors on the cell surface of the endothelial cells, there 
is an increase in vascular permeability, leading to extravasation of plasma proteins and 
dissociation of pericyte coverage (Roberts and Palade 1997; Dvorak 2005). This is followed 
by proliferation and migration of the endothelial cells to initiate new vessel formation 
(Ausprunk and Folkman 1977). For new vessel formation to occur, there also needs to be 
localized degradation of the extracellular matrix, which is performed by the matrix 
metalloproteinases, cathepsin B and other degradation enzymes, as well as the expression of 
matrix proteins such as fibronectin and laminin (Mikkelsen et al. 1995; Gladson 1999; 
Ljubimova et al. 2006). The expression of these essential extracellular matrix proteins largely 
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occurs in the tumor cells or cancer associated fibroblasts (Rasanen and Vaheri 2010), which 
then secrete them into the extracellular milieu. 
3.1.1 Angiogenesis in cholangiocarcinoma 
A recent immunohistochemical study of microvessel density and lymphatic microvessel 
density revealed that intrahepatic cholangiocarcinoma tumors demonstrated tumor-
associated angiogenesis (Thelen et al. 2009). Tumors with increased microvessel density 
were correlated with a higher recurrence rate, lower 5-year survival rates and increased 
nodal spread which in turn influences patient survival (Thelen et al. 2009). Recent studies 
have also shown that the overexpression of the angiogenic factors nerve growth factor- 
(NGF-) and vascular endothelial growth factor-C (VEGF-C) occurred in approximately 
57.1% and 46.4% of cholangiocarcinoma samples, respectively (Xu et al. 2010). A number of 
human cholangiocarcinoma cell lines and samples have also been shown to overexpress 
VEGF-A and VEGF receptors (VEGFRs), the angiogenic factors angiopoietin-1, -2, and 
thrombospondin-1, as well as EGF, EGF receptors (EGFR) and basic fibroblast growth factor 
(Ogasawara et al. 2001; Alvaro et al. 2006; Tang et al. 2006; Yoshikawa et al. 2008; Harder et 
al. 2009). Secretion of these factors may individually or co-ordinately bring about increased 
angiogenesis as demonstrated by increased microvessel density. For example, VEGF-A has 
been shown to play a role in the neovascularization of extrahepatic cholangiocarcinoma 
(Mobius et al. 2007).  
The factors that drive angiogenesis have also been shown to have distinct effects on 
cholangiocyte and cholangiocarcinoma growth in an autocrine manner (Gaudio et al. 2006; 
Tang et al. 2006; Mobius et al. 2007; Yabuuchi et al. 2009; Yoshikawa et al. 2009; Glaser et al. 
2010). Indeed, the proliferative effects of estrogen on cholangiocarcinoma cell lines have 
been attributed to a mechanism involving the upregulation of VEGF expression, as blocking 
VEGF ameliorates the estrogenic effects on proliferation (Mancino et al. 2009).  
Taken together, these data suggest that agents that block angiogenesis (by blocking VEGF 
expression, for example) may also have a direct effect on cholangiocarcinoma cell 
proliferation in addition to their anti-angiogenic effects. In support of this notion, inhibition 
of VEGFR and EGFR signaling with vandetanib (ZD6474, a tyrosine kinase inhibitor) can be 
an important approach for the management of the subset of cholangiocarcinoma that lack 
KRAS mutations and/or have EGFR amplification (Yoshikawa et al. 2009). Furthermore, 
ZD1839 (IRESSA), an orally active, selective inhibitor of EGFR tyrosine kinase has clinical 
activity against cholangiocarcinoma by stabilizing the cell cycle inhibitor, p27Kip1 and 
enhancing radiosensitivity in cholangiocarcinoma cell lines (Yabuuchi et al. 2009). 
Curcumin, a natural phenol found in tumeric has recently been shown to suppress the 
expression of VEGF and decrease the microvessel density in a hamster model of 
cholangiocarcinoma (Prakobwong et al. 2011a). In parallel, curcumin also exerts 
antiproliferative and proapoptotic effects on cholangiocarcinoma cells independent of the 
effects on angiogenesis (Prakobwong et al. 2011a; Prakobwong et al. 2011b). Similar effects 
have been shown with inhibitors of histamine synthesis (Francis et al. 2011), H3 histamine 
receptor agonists (Francis et al. 2009), and Endothelin-1 (Fava et al. 2009) just to name a few. 
The interaction between angiogenesis, angiogenic factors and cholangiocarcinoma growth 
and progression is summarized in Figure 2. 
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Fig. 2. Schematic representation of the interactions between cholangiocarcinoma and 
angiogenic factors regulating cell proliferation and angiogenesis 
3.2 Cancer associated fibroblasts 
Under normal physiological conditions, fibroblasts have a low proliferative index and only 
secrete factors needed to maintain normal tissue homeostasis (Tuxhorn et al. 2001; Beacham 
and Cukierman 2005). Indeed, normal fibroblasts provide biochemical cues that constrain 
epithelial tumor cells within their basement membrane (Tuxhorn et al. 2001; Beacham and 
Cukierman 2005). In contrast, when homeostasis is disrupted during tissue injury, stromal 
cells rapidly and reversibly alter their phenotype and proliferation rate (Tuxhorn et al. 2001). 
However, during tumorigenesis, the fibroblastic wound healing machinery lacks the 
regulatory mechanisms to revert to normal homeostasis (Tuxhorn et al. 2001). The inability 
to down-regulate the wound healing response affects stromal dynamics. Tumor-dependent 
changes in signaling and plasticity of the stroma trigger a continuum of alterations yielding 
a ‘primed’ stroma that can support and incite tumor initiation or progression (Tuxhorn et al. 
2001).  
3.2.1 Cancer-associated fibroblasts in cholangiocarcinoma 
Cancer-associated fibroblasts are the predominant cell type in the stroma of 
cholangiocarcinoma tumors (Sirica et al. 2009). Increased -smooth muscle actin-positive 
fibroblasts were correlated with shorter survival times and larger tumor sizes in resected 
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cholangiocarcinoma tissue (Chuaysri et al. 2009; Okabe et al. 2009). The origin of these 
cancer-associated fibroblasts is unknown, although a number of possibilities have been 
suggested, including hepatic stellate cells (Okabe et al. 2009), portal fibroblasts (Dranoff and 
Wells 2010) or circulating bone marrow-derived precursor cells (Shimoda et al. 2010). Given 
the apparent heterogeneous population of cancer-associated fibroblasts observed in 
cholangiocarcinoma tumors, it is highly likely that these fibroblasts are derived from more 
than one source. Recently, researchers have performed genetic screening to determine the 
differences in gene expression between cholangiocarcinoma-derived cancer-associated 
fibroblasts and non-malignant liver fibroblasts and showed a number of genes associated 
with angiogenesis, cell proliferation and motility (Utispan et al. 2010). In particular, 
periostin, a cell adhesion molecule, was shown to be significantly upregulated correlating 
with shorter survival time in patients and increased cell proliferation and invasive 
properties in vitro (Utispan et al. 2010). Another gene specifically expressed by 
cholangiocarcinoma-derived cancer-associated fibroblasts is the extracellular matrix protein 
tenascin-C (Aishima et al. 2003; Iguchi et al. 2009). This gene was expressed predominantly 
in the stroma near the invasion front of the tumor (Aishima et al. 2003) and was associated 
with poor prognosis in intrahepatic cholangiocarcinoma (Aishima et al. 2003; Iguchi et al. 
2009). Furthermore, the expression of thrombospondin-1 by cancer-associated fibroblasts 
correlated with increased metastatsis (Kawahara et al. 1998; Tang et al. 2006).  
 
Fig. 3. Summary of the signalling molecules released by cholangiocarcinoma-derived cancer-
associated fibroblasts and their known effects on cholangiocarcinoma progression. CAFs; 
cancer-associated fibroblasts, HGF; hepatocyte growth factor, SDF-1; stromal derived factor-1. 
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One last cancer-associated fibroblast gene of note is the expression of the chemokine, 
stromal-derived factor 1, which is released from stromal fibroblasts and stimulates the 
invasion and migration of cholangiocarcinoma cells via interaction with the chemokine 
receptor, CXCR4 (Ohira et al. 2006). A summary of these and other cholangiocarcinoma-
derived cancer-associated fibroblasts can be found in Figure 3. 
The preponderance of data demonstrating a role for cancer-associated fibroblasts in the 
growth and invasion of cholangiocarcinoma suggest that targeting molecular signals released 
from cancer-associated fibroblasts may be a viable option, in addition to strategies for 
suppressing cholangiocarcinoma cell proliferation, for the treatment of cholangiocarcinoma. 
3.3 Tumor-associated macrophages 
Inflammation and the immune system share a long-standing relationship with tumor initiation 
and progression. Indeed, the primary risk factor for the development of a number of different 
tumor types is chronic inflammation of the target organ (Sica 2010). Once a tumor is initiated, 
tumor-associated macrophages (TAMs) are the major immune cell found within tumors. 
Macrophages generally have the potential to express and secrete pro- and anti-inflammatory 
molecules, and as such, may have pro- and anti-tumor activities depending upon the 
activation stimulus (Sica 2010). For example, macrophages activated with tumor necrosis factor 
, (considered M1 activation), have anti-tumor activity and signal tissue destruction (Mantovani 
et al. 2002). Alternatively, in response to interleukin-4, macrophages undergo M2 activation  
and are involved in tissue repair, remodelling and tumor promotion (Mantovani et al. 2002).  
 
Fig. 4. Schematic representation of the pro- (M1) and anti-(M2) inflammatory activation of 
macrophages and their effect on tumor growth.  
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Logically, most TAMs have an M2-like phenotype (Mantovani and Sica 2010) thought to be 
brought about by various signals expressed within the tumor microenvironment, including 
interleukin-10, transforming growth factor- and colony stimulating factor-1 (Sica 2010). These 
signals responsible for the M2-activation of macrophages have been reported to come from 
myeloid-derived suppressor cells, IL-10+ B lymphocytes, Th2 subtype of T helper cells and the 
tumor cells themselves (Sica 2010). Once alternatively activated, TAMs exhibit reduced anti-
tumor activities, while increasing the production of mediators of angiogenesis such as VEGF 
and IL-10 (Mantovani and Sica 2010), as well as M2-specific genes that are known to be 
involved in promoting cell proliferation (Mantovani and Sica 2010). These events are 
summarized in Figure 4.  
It has been proposed that strategies to inhibit the M2- and activation of the M1-inducing 
signals may lead to the restoration of the anti-tumor functions of TAM and help to remove 
the protective signals originating from the M2 TAM (Sica and Bronte 2007), which may 
trigger an innate immune response, thereby reducing tumor size (Sica 2010).  
3.3.1 Tumor-associated macrophages in cholangiocarcinoma 
As mentioned previously, cholangiocarcinoma shares a long-standing relationship with 
chronic inflammation (Gores 2003). Indeed, cholangiocarcinoma cells are known to over-
produce many inflammatory cytokines, with IL-6 being the most studied (Isomoto et al. 
2007). The role of TAMs in the development and progression of cholangiocarcinoma is 
poorly understood. However, recent studies have demonstrated that the density of 
infiltrating macrophages (as demonstrated using the MAC387 antibody to specifically stain 
macrophages) was high in over half of the tumor samples studied and that a high density of 
MAC387-positive cells correlated to a poor survival rate although conclusive proof that 
these cells were of the M2-phenotype is lacking (Subimerb et al. 2010a). Similarly, a subset of 
monocytes (CD14+CD16+) thought to be the precursors of tissue-resident macrophages are 
increased in the blood from cholangiocarcinoma patients, the levels of which were 
correlated with the density of MAC387-positive infiltrating macrophages (Subimerb et al. 
2010b). The circulating CD14+CD16+ monocytes also expressed higher levels of angiogenic 
factors such as VEGF and the chemokine CXCL3 (Subimerb et al. 2010b). Lastly, Hasita et al. 
demonstrated that the macrophages infiltrating intrahepatic cholangiocarcinoma are mainly 
of the M2 phenotype (using CD163 as a marker of M2-type macrophages); their number 
correlates closely with neovascularization and infiltration of FOXP3+ regulatory T cells 
(Hasita et al. 2010). Furthermore, treatment of macrophages in culture with the supernatant 
from a number of CCA cells induced macrophage polarization toward the M2 phenotype 
and induced the macrophage-derived expression and secretion of VEGF-A, IL-10 and TGF 
(Hasita et al. 2010). Taken together, these data suggest that TAMs may play a role in 
cholangiocarcinoma progression. However, the molecules regulating the crosstalk between 
M2-type TAMs and cholangiocarcinoma cells needs to be further clarified. 
3.4 Lymphangiogenesis in cancer 
Tumor metastasis is the most lethal aspect of cancer. The spread of tumor cells is often via 
the lymphatic vasculature and the presence of tumor foci in lymph nodes is considered an 
adverse prognostic factor in most carcinomas (Achen and Stacker 2008). Metastatic spread of 
tumor cells via the lymphatic system was previously thought to be via a passive process by 
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which detached tumor cells enter pre-existing lymphatic vessels in the vicinity of the tumor 
(Achen and Stacker 2008). However, recent studies suggest that the formation of new 
lymphatic vessels in the tumor microenvironment correlates with lymphatic metastasis 
(Achen et al. 2005).  
To date, the growth factors recognized to be associated with the control of 
lymphangiogenesis are similar to those that control angiogenesis. That is, the most 
characterized factors are VEGF-C and VEGF-D, which are secreted from the tumors, and 
then activate VEGFR-3 expressed on lymphatic endothelium (Lymboussaki et al. 1998). 
Activation of VEGFR-3 induces the proliferation of lymphatic endothelial cells in vitro 
(Makinen et al. 2001) and the formation of new lymphatic vessels in vivo (Veikkola et al. 
2001). Other identified lymphangiogenic factors include VEGF-A (Nagy et al. 2002), 
fibroblast growth factor-2 (Kubo et al. 2002), angiopoietin-2 (Gale et al. 2002) and platelet-
derived growth factor-BB (Cao et al. 2004).  
Because of the overlap in angiogenic and lymphangiogenic activity of the above-mentioned 
factors, agents designed to block angiogenesis may also be effective in blocking 
lymphangiogenesis. For example, inhibitors that block the VEGF-C/VEGF-D/VEGFR3 
signalling mechanism might have the potential to not only block angiogenesis, but to also 
block lymphangiogenesis and hence to block lymphogenous metastatic spread (Baldwin et al. 
2002; Stacker et al. 2002a; Stacker et al. 2002b). Indeed, a neutralizing VEGF-D monoclonal 
antibody designed to block the interaction between VEGF-D and its receptors, inhibited 
angiogenesis, lymphangiogenesis and metastatic spread via the lymphatics in a mouse tumor 
model (Stacker et al. 2001). Further studies into therapeutic strategies designed to block 
lymphangiogenesis are required in an attempt to stop the metastatic spread of tumors.  
3.4.1 Lymphangiogenesis in cholangiocarcinoma 
The role of lymphangiogenesis in cholangiocarcinoma metastasis and progression is largely 
unknown and controversial. However, recent studies suggest that there is a correlation 
between lymphangiogenesis and lymph node metastases and prognosis; patients diagnosed 
with cholangiocarcinoma tumors exhibiting low lymphatic vessel density have a longer 
survival rate than those with higher lymphatic vessel density (Thelen et al. 2008). In 
addition, in intrahepatic cholangiocarcinoma tumors, high lymphatic vessel density 
correlated with increased nodal spread and higher recurrence rate (Thelen et al. 2009). 
Conversely, other researchers demonstrated that in intrahepatic cholangiocarcinoma 
tumors, lymph node metastasis did not correlate with lymphangiogenesis, but did correlate 
with VEGF-C expression and the presence of a subset of myofibroblasts expressing the same 
markers as lymphendothelial cells (Aishima et al. 2008), which may explain the discrepancy 
in conclusions.  
NGF has previously been linked to tumor progression and growth (Sortino et al. 2000; 
Descamps et al. 2001a; Descamps et al. 2001b) as well as VEGF expression (Lazarovici et al. 
2006a; Lazarovici et al. 2006b) in a number of other cell types. Therefore, Xu et al. assessed 
the correlation of NGF- expression with lymphangiogenesis, lymph node metastasis or 
VEGF-C expression in hilar cholangiocarcinoma tissue (Xu et al. 2010). Indeed, high NGF 
expression was correlated with VEGF-C overexpression, lymphatic vessel density, and 
lymph node metastasis suggesting that NGF may also be responsible for stimulating 
lymphangiogenesis in cholangiocarcinoma tumors. 
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4. Conclusions 
The work highlighted in this review clearly demonstrates a role for the tumor 
microenvironment in the growth, progression and metastatic invasion of 
cholangiocarcinoma. There is obviously a strong interplay between the cells found in the 
stroma and cholangiocarcinoma cells with signaling molecules passing back and forth 
between the cell types to co-ordinately support an environment that nurtures tumor growth 
and suppresses innate immunity while conferring resistance to cytotoxic insults (both 
endogenous and chemotherapeutic). The mechanism by which each of the support cells 
found in the stroma of cholangiocarcinoma tumors are recruited and activated is still largely 
unknown. Therapeutic strategies designed to target the microenvironment rather than 
specifically targeting the cholangiocarcinoma cells might prove fruitful in the quest to 
combat this devastating cancer. 
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